fbpixel

Osteoarthritis research studies for holistic treatments

Around the world over thousands of years, patients have received root-cause holistic treatment for their diseases with personalized
treatment, diet and lifestyle modification recommendations. Read the inspiring true stories of practitioners who heal people and who recovered
from their problems after Osteoarthritis treatment at their clinics. Many have been generous to share their knowledge and experience for the benefit
of other holistic experts and patients alike. Many practitioners share their Case Studies and the healing powers of Osteoarthritis and related therapies
as they heal people who benefited from our expertise.

/ title=”Efficacy Of Salvana Upanaha Sweda With And Without Abhyanga In Janu Sandhigata Vata W.S.R. To Oa.”>
Efficacy Of Salvana Upanaha Sweda With And Without Abhyanga In Janu Sandhigata Vata W.S.R. To Oa.

March 2018

Sandhigata Vata is one among the Vata Vyadhi affecting the locomotor system by deranging the major joints of the body presenting with Sandhi Shoola, Sandhi Shotha, Prasarana Akunchana Vedana and Sandhi Atopa. In modern parlance, it simulates Osteoarthritis, the prevalence of which is 80% at the age of 65 years. Bahya Snehana and Swedana are two important treatment modalities of choice in diseases pertaining to Vata. Upanaha is mentioned as the specific line of treatment in the context of Sandhigata Vata Chikitsa. Salvana Upanaha is a form of Sweda performed using Amla, Snigdha, Gandha pradhana Vatahara Dravyas which is mentioned to be beneficial in Vata vyadhi. So, the present study was planned to evaluate the therapeutic efficacy of Salvana Upanaha Sweda with and without Abhyanga in Janu Sandhigata Vata w.s.r. to OA of Knee Joint. The present study is a single blind comparative clinical study with pre – test and post – test design where in 40 patients of either sex diagnosed as Janu Sandhigatavata w.s.r. to OA were randomly assigned into two groups comprising of 20 patients in each. The patients in Group A were subjected to Sthanika Abhyanga with Ksheera Bala Taila followed by Salvana Upanaha where as the patients in Group B were subjected to Salvana Upanaha alone without Abhyanga which was retained for 12 hrs over night and the same was done for 7 Consecutive days. The overall observation in the study revealed that the maximum patients were of VataKaphaja Prakruti, females in the age group of 51 – 60 years belonging to middle class presenting with Bilateral Osteoarthritis of the Knee Joint. The overall effect of treatment in Janu Sandhigata Vata w.s.r. to OA has shown statistically highly significant result with in both the groups. But, by taking into account the t value of both the groups which revealed that the patients in Group A treated with Sthanika Abhyanga and Salvana Upanaha showed comparatively better results than the patients in Group B treated with only Salvana Upanaha without Abhyanga. The present study revealed that the combined effect of Bahya Snehana in the form of Sthanika Abhyanga and Swedana in the form of Salvana Upanaha is found beneficial in treating Sandhigata Vata.

/ onclick=”MoreLine(‘16311’, ‘Efficacy Of Salvana Upanaha Sweda With And Without Abhyanga In Janu Sandhigata Vata W.S.R. To Oa.’)”>
…more

/ title=”Stigmasterol: a phytosterol with potential anti-osteoarthritic properties.”>
Stigmasterol: a phytosterol with potential anti-osteoarthritic properties.

September 2009

OBJECTIVE:
Although most studies have focused on the cholesterol-lowering activity of stigmasterol, other bioactivities have been ascribed to this plant sterol compound, one of which is a potential anti-inflammatory effect. To investigate the effects of stigmasterol, a plant sterol, on the inflammatory mediators and metalloproteinases produced by chondrocytes. METHOD: We used a model of newborn mouse chondrocytes and human osteoarthritis (OA) chondrocytes in primary culture stimulated with or without IL-1beta (10ng/ml), for 18h. Cells were pre-incubated for 48h with stigmasterol (20mug/ml) compared to untreated cells. We initially investigated the presence of stigmasterol in chondrocyte, compared to other phytosterols. We then assessed the role of stigmasterol on the expression of various genes involved in inflammation (IL-6) and cartilage turn-over (MMP-3, -13, ADAMTS-4, -5, type II collagen, aggrecan) by quantitative Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR). Additional experiments were carried out to monitor the production of MMP-3 and prostaglandin E2 (PGE(2)) by specific immuno-enzymatic assays. We eventually looked at the role of stigmasterol on NF-kappaB activation by western blot, using an anti-IkappaBalpha antibody.
Results:
After 18h of IL-1beta treatment, MMP-3, MMP-13, ADAMTS-4, but not ADAMTS-5 RNA expression were elevated, as well as MMP-3 and PGE(2) protein levels in mouse and human chondrocytes. Type II collagen and aggrecan mRNA levels were significatively reduced. Pre-incubation of stigmasterol to IL-1beta-treated cells significantly decreased these effects described above (significant reduction of MMP-3 mRNA in human and mouse, MMP-3 protein in mouse, MMP-13 mRNA in mouse and human, ADAMTS-4 mRNA in human, PGE(2) protein in human and mouse) Finally, stigmasterol was capable of counteracting the IL-1beta-induced NF-kappaB pathway.
Conclusion:
This study shows that stigmasterol inhibits several pro-inflammatory and matrix degradation mediators typically involved in OA-induced cartilage degradation, at least in part through the inhibition of the NF-kappaB pathway. These promising results justify further ex vivo and in vivo investigations with stigmasterol.

/ onclick=”MoreLine(‘11674’, ‘Stigmasterol: a phytosterol with potential anti-osteoarthritic properties.’)”>
…more

/ title=”Betulinic acid inhibits IL-1?-induced inflammation by activating PPAR-? in human osteoarthritis chondrocytes.”>
Betulinic acid inhibits IL-1?-induced inflammation by activating PPAR-? in human osteoarthritis chondrocytes.

September 2015

Betulinic acid (BA), a triterpenoid isolated from birch bark, has been reported to have anti-inflammatory effects. In this study, we investigated the anti-osteoarthritic effects of BA in IL-1?-stimulated human osteoarthritis chondrocytes. Human osteoarthritis chondrocytes were pre-incubated with BA (6, 12, 24?M) for 12h and then treated with IL-1? (10ng/ml). The production of PGE2 and NO were detected by ELISA and Griess reagent. The expression of NF-?B, I?B, and PPAR-? were detected by Western blotting. The results showed that BA dose-dependently inhibited IL-1?-induced MMP-1, MMP-3, MMP-13, PGE2 and NO productions. BA also inhibited IL-1?-induced NF-?B activation. Furthermore, BA was found to activate PPAR-? and the inhibition of PGE2 and NO by BA can be reversed by PPAR-? antagonist GW9662. In conclusion, these results suggested that BA inhibited IL-1?-induced inflammation in osteoarthritis chondrocytes by activating PPAR-?.

/ onclick=”MoreLine(‘11004’, ‘Betulinic acid inhibits IL-1?-induced inflammation by activating PPAR-? in human osteoarthritis chondrocytes.’)”>
…more

/ title=”Relative efficacies of omega-3 polyunsaturated fatty acids in reducing expression of key proteins in a model system for studying osteoarthritis.”>
Relative efficacies of omega-3 polyunsaturated fatty acids in reducing expression of key proteins in a model system for studying osteoarthritis.

July 2009

OBJECTIVE:
To assess the relative efficacy of three different omega-3 (n-3) polyunsaturated fatty acids (PUFAs) in suppressing the mRNA levels for important proteins involved in the etiology of osteoarthritis (OA).
METHODS:
A model cell culture system (bovine chondrocytes) was used. Inflammatory factors and enzymes involved in OA were induced by exposure of the chondrocyte cultures to interleukin-1alpha (IL-1alpha). The effect of pre-incubating cultures with various amounts of exogenous fatty acids on subsequent levels of mRNAs was assessed by reverse transcription-polymerase chain reactions (RT-PCR).
Results:
Exposure of cultures to IL-1alpha induced expression of the cartilage proteinases A Disintegrin And Metalloproteinase with ThromboSpondin motifs (ADAMTS)-4 and ADAMTS-5, cyclooxygenase (COX)-2, the matrix metalloproteinase (MMP)-3 and the inflammatory cytokines IL-1alpha, interleukin-1beta (IL-1beta) and tumour necrosis factor-alpha (TNF-alpha). n-3 PUFAs were able to reduce the levels of mRNA for ADAMTS-4, ADAMTS-5, MMP-3, MMP-13, COX-2 (but not COX-1), IL-1alpha, IL-1beta and TNF-alpha. Eicosapentaenoic acid (EPA) was the most effective, followed by docosahexaenoic (DHA) and then alpha-linolenic (ALA) acid. The n-6 PUFA, arachidonic acid (AA) had no effect.
Conclusion:
These results show that omega-3 (n-3) PUFAs cause a reduction in the mRNA levels for various proteins known to be important in the pathology of OA. They provide a molecular explanation, at least in part, for beneficial effects of dietary omega-3 PUFAs for the amelioration of symptoms of the . The relative efficacy of EPA suggests that this omega-3 PUFA may be especially useful for dietary supplementation in patients with OA.

/ onclick=”MoreLine(‘10986’, ‘Relative efficacies of omega-3 polyunsaturated fatty acids in reducing expression of key proteins in a model system for studying osteoarthritis.’)”>
…more

/ title=”Curcumin synergistically potentiates the growth-inhibitory and pro-apoptotic effects of celecoxib in osteoarthritis synovial adherent cells.”>
Curcumin synergistically potentiates the growth-inhibitory and pro-apoptotic effects of celecoxib in osteoarthritis synovial adherent cells.

February 2006

OBJECTIVES:
Osteoarthritis (OA) is the Western world’s leading cause of disability. Cyclo-oxygenase-2 (COX-2) inhibitors are efficient anti-inflammatory agents commonly used in the treatment of osteoarthritis. However, recent studies have shown that their long-term use may be limited due to cardiovascular toxicity. The anti-inflammatory efficacy of the phytochemical curcumin has been demonstrated in several in vitro and animal models. This study was undertaken to investigate whether curcumin augments the growth-inhibitory and pro-apoptotic effects of celecoxib in OA synovial adherent cells.
METHODS:
OA synovial adherent cells were prepared from human synovial tissue collected during total knee replacement surgery. The cells were exposed to different concentrations of celecoxib (0-40 mum), curcumin (0-20 mum) and their combination. Flow cytometric analysis was used to measure the percentage of cells with a subdiploid DNA content, the hallmark of apoptosis. COX-2 activity was assessed by measuring production of prostaglandin E(2) by enzyme-linked immunoassay.
Results:
A synergistic effect was observed in inhibition of cell growth when the cells were exposed to various concentrations of celecoxib combined with curcumin. The inhibitory effect of the combination on cell growth was associated with an increased induction of apoptosis. The synergistic effect was mediated through a mechanism that involves inhibition of COX-2 activity. CONCLUSIONS: This effect may enable the use of celecoxib at lower and safer concentrations, and may pave the way for a novel combination treatment in osteoarthritis and other rheumatological disorders.

/ onclick=”MoreLine(‘10963’, ‘Curcumin synergistically potentiates the growth-inhibitory and pro-apoptotic effects of celecoxib in osteoarthritis synovial adherent cells.’)”>
…more

/ title=”Efficacy of methylsulfonylmethane (MSM) in osteoarthritis pain of the knee: a pilot clinical trial.”>
Efficacy of methylsulfonylmethane (MSM) in osteoarthritis pain of the knee: a pilot clinical trial.

March 2006

OBJECTIVE:
Osteoarthritis (OA) is the most common form of arthritis and the second most common cause of long-term disability among middle-aged and older adults in the United States. Methylsulfonylmethane (MSM) is a popular dietary supplement used as a single agent and in combination with other nutrients, and purported to be beneficial for arthritis. However, there is paucity of evidence to support the use of MSM.
METHODS:
A randomized, double-blind, placebo-controlled trial was conducted. Fifty men and women, 40-76 years of age with knee OA pain were enrolled in an outpatient medical center. Intervention was MSM 3g or placebo twice a day for 12 weeks (6g/day total). Outcomes included the Western Ontario and McMaster University Osteoarthritis Index visual analogue scale (WOMAC), patient and physician global assessments ( status, response to therapy), and SF-36 (overall health-related quality of life).
Results:
Compared to placebo, MSM produced significant decreases in WOMAC pain and physical function impairment (P<0.05). No notable changes were found in WOMAC stiffness and aggregated total symptoms scores. MSM also produced improvement in performing activities of daily living when compared to placebo on the SF-36 evaluation (P<0.05).
Conclusion:
MSM (3g twice a day) improved symptoms of pain and physical function during the short intervention without major adverse events. The benefits and safety of MSM in managing OA and long-term use cannot be confirmed from this pilot trial, but its potential clinical application is examined. Underlying mechanisms of action and need for further investigation of MSM are discussed.

/ onclick=”MoreLine(‘10945’, ‘Efficacy of methylsulfonylmethane (MSM) in osteoarthritis pain of the knee: a pilot clinical trial.’)”>
…more